Roche Annual General Meeting 2023
- All proposals of the Board of Directors approved
- Severin Schwan elected as new Chairman of the Board of Directors; all other members of the Board of Directors standing for election were elected
- Thomas Schinecker new Roche Group CEO as of today
- 36th dividend increase in succession to CHF 9.50 per share and non-voting equity security
Basel, 14 March 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the ordinary Annual General Meeting has elected Severin Schwan as the new Chairman of the Board of Directors with 98.32% of the votes and has approved all of the Board's proposals. The 574 shareholders present, who represented 75.94% of the total of 106,691,000 shares, approved the Management Report, the Financial Statements and the Consolidated Financial Statements for 2022, the Remuneration Report and the revision of the Articles of Incorporation.
The newly elected Chairman of the Board of Directors, Severin Schwan, addressed the shareholders in a speech: "Overall, we achieved good results last year; the base business of the Diagnostics Division and our newer medicines continued their strong growth. I would like to thank our outgoing Chairman Christoph Franz for his long and trusting cooperation. Today, Thomas Schinecker will assume my role as CEO of the Roche Group. I look forward to our future cooperation."
The shareholders also approved an increase in the dividend for the past financial year to 9.50 Swiss francs (gross) per share and non-voting equity security. This is the 36th consecutive dividend increase. They also authorised ratification of the actions of the members of the Board of Directors and the Corporate Executive Committee.
Christoph Franz, the departing Chairman of Roche's Board of Directors, expressed his gratitude for the trust shown by the shareholders and said: "It was an exceptional honour and pleasure for me to have been able to work for this unique company for many years. The owner family's long-term orientation motivates the Board of Directors and the Corporate Executive Committee to invest consistently in top-level research so that the company can continue making major contributions to people’s health. I would like to thank the founding families for their strong support."
Shareholders approved total bonuses for the 2022 financial year of 98.82% for the Corporate Executive Committee and of 97.02% for the Chairman of the Board of Directors. They also approved a maximum total future remuneration of 99.04% for the Board of Directors and of 98.95% for the Corporate Executive Committee until the 2023 Annual General Meeting.
In addition to Severin Schwan, the following directors standing for election were re-elected to the Board of Directors for a term of office of one year:
- André Hoffmann
- Dr Jörg Duschmalé
- Dr Patrick Frost
- Anita Hauser
- Professor Dr Richard P. Lifton
- Bernard Poussot
- Dr Claudia Süssmuth Dyckerhoff
- Dr Jemilah Mahmood
The following persons standing for election were elected to the Board of Directors for a term of office of one year for the first time:
- Professor Dr Akiko Iwasaki
- Dr Mark Schneider
The following members of the Board of Directors were elected as members of the Remuneration Committee for a term of office of one year:
- André Hoffmann
- Professor Dr Richard P. Lifton
- Bernard Poussot
- Dr Jörg Duschmalé
- Anita Hauser
The Meeting appointed KPMG AG as external auditor for the 2023 financial year and Testaris AG as independent proxy until the conclusion of the 2024 ordinary Annual General Meeting.
As of today, Thomas Schinecker will take over from Severin Schwan as CEO of the Roche Group. He too addressed the shareholders in a speech: "With its combination of pharmaceuticals, diagnostics and digitalisation, Roche has an unsurpassed position in terms of helping people to diagnose their illnesses as quickly as possible and to treat or even cure them. The entire Roche team, with our 100,000-plus employees as well as our partners, will continue to do our utmost to make our medical innovations available globally to as many people as possible and as rapidly as possible."
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: email@example.com
|Hans Trees, PhD|
Phone: +41 79 407 72 58
Phone: +41 79 771 05 25
Phone: +41 79 461 86 83
Phone: +41 79 327 54 74
|Dr. Barbara von Schnurbein|
Phone: +41 79 699 97 44
Phone: +41 79 935 81 48
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Fixing of coupon rates - Nykredit Realkredit A/S23.3.2023 12:34:03 CET | Press release
To Nasdaq Copenhagen FIXING OF COUPON RATES 23 March 2023 Fixing of coupon rates effective from 27 March 2023 Effective from 27 March 2023, the coupon rates of floating-rate bonds issued by Nykredit Realkredit A/S will be adjusted. Bonds with quarterly interest rate fixing The new coupon rates will apply from 27 March 2023 to 27 June 2023: Uncapped bonds DK0030486246, (SNP), maturity in 2024, new rate as at 27 March 2023: 3.9900% pa DK0030492053, (SNP), maturity in 2023, new rate as at 27 March 2023: 3.9900% pa DK0030494851, (SNP), maturity in 2023, new rate as at 27 March 2023: 3.7400% pa Questions may be directed toInvestor Relations at firstname.lastname@example.org Rikke Gredsted Seidenfaden, Head of Press Relations,tel +45 44 55 14 49. Attachment Fixing of coupon rates - Nykredit Realkredit - 20230323
Fastsættelse af kuponrenter - Nykredit Realkredit A/S23.3.2023 12:34:03 CET | pressemeddelelse
Til Nasdaq Copenhagen FASTSÆTTELSE AF KUPONRENTER 23. marts 2023 Fastsættelse af kuponrenter gældende fra den 27. marts 2023 Med virkning fra den 27. marts 2023 ændres kuponrenten på variabelt forrentede obligationer udstedt af Nykredit Realkredit A/S. Obligationer med kvartårlig rentefastsættelse De nye kuponrenter er gældende fra den 27. marts 2023 til den 27. juni 2023: Obligationer uden renteloft DK0030486246, (SNP), udløb 2024, ny rente pr. 27. marts 2023: 3,9900% p.a. DK0030492053, (SNP), udløb 2023, ny rente pr. 27. marts 2023: 3,9900% p.a. DK0030494851, (SNP), udløb 2023, ny rente pr. 27. marts 2023: 3,7400% p.a. Spørgsmål kan rettes til Investor Relations på email@example.com pressechefRikke Gredsted Seidenfaden, telefon 44 55 14 49. Vedhæftet fil Fastsættelse af kuponrenter – Nykredit Realkredit - 20230323
Dassault Aviation: Availability of a complete form of the 2022 Annual Financial Report CLARIFICATION23.3.2023 12:32:18 CET | Press release
Availability of a complete form of the 2022 Annual Financial Report CLARIFICATION On March 21, 2023, Dassault Aviation made available to the public and filed with the Autorité des Marchés Financiers the complete version of the 2022 Annual Financial Report (Rapport financier annuel) of Dassault Aviation as of 31 December 2022, including in ESEF format. Dassault Aviation announces that the following statement has been added today to the PDF version of said report: “This document is a reproduction of the official version of 2022 Annual financial report, which was established in XHTML and filed with the French Markets Authority (AMF), available on the Company’s website (www.dassault-aviation.com)” This financial annual report can be found on the Company’s website at www.dassault-aviation.com, in the “Finance / Regulated information / 2023” and “Finance / Publications / 2023 Publications” sections. ABOUT DASSAULT AVIATION: With over 10,000 military and civil aircraft (including 2,500 Falcon
Ria Money Transfer to sponsor FC Internazionale Milano23.3.2023 12:00:27 CET | Press release
Ria Money Transfer expects this new sponsorship, which extends through the 2025 season, will have a positive impact for the local community BUENA PARK, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Ria Money Transfer, a global leader in the cross-border money transfer industry and business segment of Euronet (NASDAQ: EEFT), today announced an agreement to become an official sponsor of the Italian football club FC Internazionale Milano through the 2025 season. This new sports sponsorship will help raise awareness of Ria’s brand in Italy and benefit Euronet’s Money Transfer segment, which includes Ria Money Transfer, Xe and Dandelion globally. Thanks to this sponsorship, Ria will be able to foster a closer relationship with Inter’s far-reaching fanbase of more than 500 million fans distributed on all continents. Inter’s global appeal makes it a perfect fit for Ria, whose reach extends across more than 180 countries and territories. This association boosts the visibility of the brands in Eur
Bombardier Updates 2025 Strategic Objectives to Reflect Strong Performance and Solid Business Fundamentals23.3.2023 12:00:00 CET | Press release
MONTRÉAL, March 23, 2023 (GLOBE NEWSWIRE) -- Bombardier (BBD-B.TO) will host its 2023 Investor Day this morning. Éric Martel, Bombardier’s President and CEO, along with Paul Sislian, Executive Vice President, Aftermarket Services & Strategy, and Bart Demosky, Executive Vice President and Chief Financial Officer, will present an overview of the company’s solid progress made and new opportunities for diversified growth. “In 2021, we laid the foundation for a stronger, more resilient and predictable Bombardier by 2025. Halfway down the road, we can say we are delivering on that promise,” said Martel. “All of Bombardier’s strategic priorities are on track or ahead of plan. We are therefore proud to announce today that we are confidently raising the bar. The future is bright for Bombardier. While we are carefully monitoring the current market situation, we know that we have all the ingredients in place to remain a driving force in the industry. Our financial performance allows us to secure